Komori
Share Issuance and Disposal4556KAINOS Laboratories,Inc.Pharmaceuticals

Notice Regarding Approval Resolutions on a Share Consolidation, the Abolition of the Provisions on the Number of Shares per Trading Unit, and Partial Amendments to the Articles of Incorporation

At the extraordinary general meeting of shareholders, the consolidation of 235,000 shares into 1 share, the abolition of the share unit system and the amendments to the Articles of Incorporation were approved as originally proposed. As a result, the Company's shares are scheduled to be delisted on 11 June 2026.

Worth reading
28Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
235000
Reverse stock split of shares into 1 share
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Share Consolidation

発行・処分する株式数

Consolidation of 235,000 shares into 1 share

Offering structure
Major shareholders after the offering
Expected to consist solely of Flowers株式会社 and 旭化成トラピューティクス株式会社
Stock Split RatioNot applicable because this is a share consolidation
Procedures under the Corporate Code of Conduct
Each proposal was submitted to the extraordinary general meeting of shareholders and approved as originally proposed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalShare Consolidation
Number of shares to be issued or disposed ofConsolidation of 235,000 shares into 1 share
Total number of issued shares4,394,960 shares → 18 shares
Stock Split RatioNot applicable because this is a share consolidation
Procedures under the Corporate Code of ConductEach proposal was submitted to the extraordinary general meeting of shareholders and approved as originally proposed
Major shareholders after the offeringExpected to consist solely of Flowers株式会社 and 旭化成トラピューティクス株式会社
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentMost recent equity financingImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To make the tender offeror and the shareholders who agreed not to tender their shares the Company's only shareholders and take the Company's shares private. Following the share consolidation, provisions in the Articles of Incorporation concerning the share unit system, the acquisition of treasury shares, record dates and electronic provision measures will no longer be necessary.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Approval Resolutions on a Share Consolidation, the Abolition of the Provisions on the Number of Shares per Trading Unit, and Partial Amendments to the Articles of Incorporation | KAINOS Laboratories,Inc. (4556) timely disclosure | Komori